PharmExec Blog

Coming Soon: Cancer Wars

Photo by Lawrence WhittemoreWhat if the industry develops highly effective cancer treatments and no one pays for them? BusinessWeek takes on the question in a reasonably savvy brief article this week. A sample:

“At some point—and that point will come sooner rather than later—payers are not going to approve spending $100,000 for someone to live an extra six months,” says Erik Gordon, director of biomedicine at Stevens Institute of Technology. David Balekdjian, a partner at strategy consulting firm the Bruckner Group, confirms that “for many diseases, U.S. insurers are rigorously examining the outcomes new drugs produce, relative to their cost.” As insurers increasingly scrutinize cancer drugs, “many will never reach their markets,” Balekdjian warns.

And in case you missed it, here’s a link to a piece we published last year featuring a prescient conversation on the same topic between pharma cancer heavyweights Bruce Seeley (of Genentech), Robert LaCaze (Bristol-Myers Squibb), and Allison Ayers (Pfizer).

Photo by Lawrence Whittemore

This entry was posted in Strategy and tagged , , . Bookmark the permalink. Post a comment or leave a trackback: Trackback URL.

One Comment

  1. Posted May 24, 2012 at 8:07 pm | Permalink

    composed by sbsbsb0416 Thanks, beautiful site with great informational content. This is a really interesting and informative content.

Post a Comment

Your email is never published nor shared. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta